User blogs

Hangzhou’s Yuhang District is showcasing its edge in high technology, culture and environment in a bid to lure more investment and talent at the second China International Import Expo.The second China International Import Expo will be held at the National Exhibition and Convention Center in Shanghai from November 5 to 10, 2019.For further information about China International Import Expo, please visit: https://www.shine.cn/China-International-Import-Expo/ or
https://www.shine.cn/ciie2019/v1.To get more CIIE 2019, you can visit shine news official website.

The Yuhang exhibition booth was designed on theme of ancient Liangzhu city, which was inscribed on the UNESCO World Heritage List in July. Organizers used multimedia and replicated Liangzhu artifacts to showcase the millennia-old civilization on the spot.

Two Yuhang-based companies participated in the expo on behalf of the district. Panex is one of the largest cross-border logistics companies in Hangzhou. Its business covers Canada, New Zealand, Australia, the Netherlands, the UK, Norway, Finland, Japan and the US, including 16 overseas subsidiaries and 45 overseas warehouses with a total area of 200,000 square meters.One of its subsidiaries, 50N Natural Ecology Group Ltd in Vancouver displayed Canadian specialties at the expo, including seafood, maple water and flaxseed oil.

Java Coffee Machine, the US subsidiary of Wanshida Co, launched a series of new products using the Internet of Things and online payments.The Yuhang government gathered 300 delegates from local government departments, organizations and companies to draw experience from other countries in tourism, education, medical services and commerce.

Before the CIIE, the Yuhang District government invited about 120 delegates from Shanghai-based organizations and companies to its cooperation seminar to seek more business opportunities from Shanghai.

At the seminar, Yuhang signed contracts with 13 enterprises, including six new manufacturing and four digital economic projects.The government also announced the establishment of an innovation center, Dream Town, in Shanghai.

Dream Town, a heaven for Internet industry startups, is in the center of Future Sci-tech City, which is a noted incubator for high-tech businesses in Hangzhou. In May, it introduced 5G in its China (Hangzhou) 5G Innovation Park, becoming one of the forerunners in the new technology in China.

The innovation center will be set up in Zhangjiang Hi-tech Park in Shanghai. It is expected to be a bridgehead for attracting hi-tech talent and promising projects for Yuhang District.It also aims to be a platform for university students to start up new business. The center creates an embryo for startups, and then transfers them to Yuhang for further research and development.Meanwhile, the center is going to give a boost to the Yangtze River Delta integration. Shanghai and Yuhang could work together more closely through this platform.

Today, artificial intelligence, fashion and digital industries are the economic engines of Yuhang. By the end of September, the digital economy had accounted for 59.9 percent of the district’s gross domestic product — the highest prorportion in Zhejiang Province.

Over 30 global enterprises are showcasing their innovative practices on the sidelines of the China International Import Expo.The second China International Import Expo will be held at the National Exhibition and Convention Center in Shanghai from November 5 to 10, 2019.For further information about China International Import Expo, please visit: https://www.shine.cn/China-International-Import-Expo/ or
https://www.shine.cn/ciie2019/v1.To get more China International Import Expo, you can visit shine news official website.

The exhibition, organized by Shanghai Daily, Eastday.com and The Paper, opened on November 1 at Shanghai Tower, the city’s tallest building and the world’s second-tallest, in Shanghai’s iconic Lujiazui financial zone. It will run through Friday.

Dozens of journalists from around the world reporting on the CIIE visited the exhibition on Thursday. Senior officials with some of the enterprises shared their visions in helping Shanghai’s role in the global innovation landscape.With texts, photos and samples on display on the building's B2 floor, the exhibition looks at the companies' innovative achievements, showcasing their involvement in the city’s infrastructure projects, engagement in local innovation networks and their efforts in promoting sustainable communities.

Honeywell delivers high-tech solutions ranging from aerospace to control technologies for buildings and industry, and performance materials, as well as the Internet of Things, said Lydia Lu, vice president of communications at Honeywell Asia High Growth Regions.

As a major CIIE exhibitor, Honeywell mainly displays connected aircraft, smart construction, intelligent manufacturing, connect supply chain and safety production solutions. Many of the technologies are on display in China for the first time.

Shanghai is home to Honeywell’s Asia-Pacific headquarters and its R&D center. It cooperates with local universities, colleges, research institutions and companies to promote the transformation of technological achievements into real products.

UFI Filters, a global leader in filtration technology and thermal management, is displaying its UFI Multitube, a new engine air filter to help cut emissions.

UFI chose Shanghai as one of its innovation centers because China is the largest automotive market, where the new-energy vehicle sector and concepts develop faster than in other countries, said Carlo Nizia, supervisor of the board of directors with UFI Filters (Shanghai) Co. He said UFI’s Shanghai R&D Center will become the group’s center of excellence.

Raloxifene Powder is approved for the prevention and treatment of osteoporosis in postmenopausal women. It is in a class of drugs called estrogen agonists/antagonists that have been developed to provide the beneficial effects of estrogens without all of the potential disadvantages. It is neither an estrogen nor a hormone. Raloxifene is sometimes called a selective estrogen receptor modulator (SERM).wisepoqder β-agonist Powder

Raloxifene reduces the risk of spine fractures. There are no data showing that raloxifene reduces the risk of hip and other non-spine fractures. For both prevention and treatment, raloxifene is taken daily as a 60 mg tablet, with or without meals.

Raloxifene appears to decrease the risk of estrogen-dependent breast cancer by 65 percent over eight years. It is FDA-approved to decrease the risk of invasive breast cancer in postmenopausal women with osteoporosis and even in women without osteoporosis who are at high risk of breast cancer. Raloxifene does not reduce the risk of coronary heart disease.

Side Effects

Side effects include hot flashes, leg cramps and an increased risk of deep vein thrombosis (blood clots). Other side effects include swelling and temporary flu-like symptoms. Raloxifene is not associated with diseases of the uterus or ovaries and does not affect cognitive (mental) function.

Raloxifene should not be taken by women at increased risk for stroke. This includes women who have had previous strokes, transient ischemic attacks (TIAs), atrial fibrillation (a type of serious irregular heart beat) or uncontrolled hypertension (high blood pressure).

The combination of anastrozole and fulvestrant extended median survival of women with hormone-receptor–positive metastatic breast cancer when compared with standard therapy of either anastrozole alone or sequential anastrozole and fulvestrant, according to study results.wisepoqder Anastrozole powder

In prior studies, anastrozole (Arimidex, AstraZeneca) exhibited the ability to suppress estrogen production, while fulvestrant (Faslodex, AstraZeneca) demonstrated high efficacy in a low-estrogen environment. In addition, the combination of fulvestrant and an aromatase inhibitor — compared with either agent alone — delayed the development of resistance by down-regulating several signaling molecules involved in the development of resistance.

To determine whether the combination of anastrozole and fulvestrant would be superior to anastrozole alone as first-line therapy for metastatic breast cancer, Rita Mehta, MD, and colleagues from the UC Irvine Medical Center conducted a phase 3 randomized trial of 694 postmenopausal women with previously untreated metastatic disease from June 1, 2004, to July 1, 2009.

During the study, patients were randomly assigned to receive either 1 mg of anastrozole orally once daily in combination with injections of fulvestrant — given in sequential dosing on the first day, every 2 weeks, and then once every 28 days after the first month — or 1 mg of anastrozole orally once daily, with possible crossover to fulvestrant alone following disease progression.

Median PFS was 15 months for patients who received the anastrozole and fulvestrant combination vs. 13.5 months for patients who received anastrozole alone, according to study results. The combination was observed to be generally more effective than anastrozole alone in all subgroups, with no significant interactions.

In addition, median OS was longer among patients assigned to the combination therapy (47.7 months vs. 41.3 months), despite the fact that 41% of the patients in the anastrozole group crossed over to fulvestrant after progression.

“The improvement in overall survival that was observed in our study has not been seen in other trials of first-line hormonal therapy for HR-positive metastatic breast cancer,” the researchers wrote. “Specifically, in the trials comparing aromatase-inhibitor therapy with tamoxifen therapy, the benefit from aromatase inhibitors with respect to progression-free survival failed to translate into a benefit with respect to overall survival, a finding that was attributed to the crossover of some patients in the tamoxifen group to an aromatase inhibitor.”

Three deaths that were possibly associated with treatment occurred in the combination group. Toxic effects of grade-4 or higher were observed in four patients who received anastrozole alone (1.2%) and in five patients who received combination therapy (1.4%; P=1.00). The four observed grade-4 toxic effects among patients who received anastrozole alone included thrombosis or embolism, joint pain, thrombocytopenia and dyspnea. Two patients in the combination group experienced grade 4-toxic effects. One experienced thrombosis or embolism, and the other experienced neutropenia or lymphopenia.

“The results of our study suggest that trials of adjuvant therapy should be performed in which the combination of an aromatase inhibitor and high-dose fulvestrant is compared with an aromatase inhibitor alone or high-dose fulvestrant alone in patients with estrogen-receptor–positive tumors for whom chemotherapy is not necessary,” the researchers concluded.

Hydrochlorothiazide is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention.Triamterene is a potassium-sparing diuretic that also prevents your body from absorbing too much salt and keeps your potassium levels from getting too low.wisepoqder Triamterene

Hydrochlorothiazide and triamterene is a combination medicine used to treat fluid retention (edema) and high blood pressure (hypertension).hydrochlorothiazide and triamterene is usually given to people in whom other diuretics have caused hypokalemia (low potassium levels in your blood).Hydrochlorothiazide and triamterene may also be used for purposes not listed in this medication guide.

Important Information
You should not use this medicine if have kidney disease, urination problems, high levels of potassium in your blood, or if you are taking other diuretics similar to triamterene. Do not use potassium supplements, salt substitutes, or low-sodium milk unless your doctor has told you to.

This medicine can raise your blood potassium to dangerous levels, especially if you have kidney disease, diabetes, severe illness, or if you are an older adult. Call your doctor right away if you have signs of high potassium: nausea, slow or unusual heart rate, numbness, tingling, muscle weakness, or loss of movement in any part of your body.

Before taking this medicine
You should not use hydrochlorothiazide and triamterene if you are allergic to hydrochlorothiazide (HCTZ, HydroDiuril, Lotensin HCT, Zestoretic, and others) or triamterene (Dyrenium), or if:

you have kidney disease or are unable to urinate;
you have high potassium levels (hyperkalemia);
you are taking diuretics similar to triamterene, such as amiloride (Midamor, Moduretic), spironolactone (Aldactone, Aldactazide); or
you are taking potassium supplements (unless your doctor tells you to).
Diuretics such as triamterene can raise your blood potassium to dangerous levels. This is more likely to occur if you have kidney disease, diabetes, severe illness, or if you are an older adult. Ask your doctor about your individual risk.

This drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is a combination of two "water pills" (diuretics): triamterene and hydrochlorothiazide. This combination is used by people who have developed or are at risk for having low potassium levels on hydrochlorothiazide. It causes you to make more urine, which helps your body get rid of extra salt and water.wisepoqder β-agonist Powder

This medication also reduces extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, or kidney disease. This can lessen symptoms such as shortness of breath or swelling in your ankles or feet.

How to use Triamterene-Hydrochlorothiazid

Take this medication by mouth as directed by your doctor, usually once daily in the morning with or without food. It is best to avoid taking this medication within 4 hours of your bedtime to prevent having to get up to urinate.

If you also take certain drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take this product at least 4 hours before or at least 4 to 6 hours after these medications.The dosage is based on your medical condition and response to treatment.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.

Tell your doctor if your condition does not improve or if it worsens (for example, your blood pressure readings increase).

The oral beta-blockers approved for migraine prophylaxis may not be effective for acute attacks because of slow absorption and modification by first-pass metabolism, which delays effective plasma levels for hours or even days. With timolol eyedrops, maxi­mum plasma concentration is achieved within 15 minutes of administration. In a pilot study, Cossack et al. tested the effectiveness of the eyedrops as an abortive migraine treatment and found it helpful for some patients.wisepoqder Timolol powder

This placebo-controlled crossover study was conducted among 10 adults with recurrent migraine, with or with­out aura, who were recruited from the authors’ neurology and ophthalmology clinics. Patients were assigned ran­domly to receive timolol maleate 0.5% or artificial tears (placebo) and were instructed to insert 1 drop in each eye at migraine onset and 30 minutes later. The participants were seen monthly for 4 months (5 visits per patient). After a 3-day washout at the 2-month mark, they were switched to the opposite treatment arm. Patients ranked the se­verity of each migraine attack on a scale of 0 (least) to 3 (greatest) and rated the effectiveness of each treatment on a scale of 1 (least) to 4 (greatest).

Among the 10 patients, 198 migraine attacks occurred during the study period. Four patients reported that timolol was highly effective in comparison to place­bo; another patient noted the opposite. Thirty-seven (67%) of 55 migraines that occurred during timolol use had severity of none to mild at 2 hours, versus 58 (75%) of the 77 migraines during placebo use. No adverse events were observed during the study.

Terbutaline may be a safe and effective treatment option for prevention of nocturnal hypoglycemia in patients with type 1 diabetes.wisepoqder Terbutaline

Researchers of a randomized, controlled trial examined whether terbutaline prevented nocturnal hypoglycemia without causing morning hyperglycemia in 15 patients with type 1 diabetes.

Patients randomly assigned to 2.5 mg terbutaline (Brethine, Novartis) had a mean nadir nocturnal plasma glucose concentration of 100 mg/dL compared with 122 mg/dL with 5 mg terbutaline and 87 mg/dL with placebo (see chart). In the 2.5-mg terbutaline group, seven patients reached nadir nocturnal concentrations <70 mg/dL, six reached concentrations <60 mg/dL and two reached concentrations <50 mg/dL. Further, three patients assigned to 5-mg terbutaline reached nadir levels <70 mg/dL; none of these patients reached any level lower than that.

Morning plasma glucose levels were 127 mg/dL with 2.5 mg terbutaline, 183 mg/dL with 5 mg terbutaline and 113 mg/dL with placebo.

"These data confirm a high frequency of nocturnal hypoglycemia in patients with aggressively treated type 1 diabetes. These data also confirm that bedtime administration of 5 mg terbutaline effectively prevents nocturnal hypoglycemia," the researchers wrote.
Hypoglycemia is the limiting step to glycemic control in patients with diabetes. It can be serious and is occasionally fatal. The majority of hypoglycemic episodes occur at night. Therefore, efforts to reduce the risk of nocturnal hypoglycemia would be well directed. The group of Cryer et al at Washington University have made a life career of addressing the biology of hypoglycemia. This report is a follow-up of earlier work from the same laboratory showing a beneficial effect of terbutaline (5 mg) in decreasing hypoglycemia overnight, but that dose was associated with undesirable hyperglycemia in the morning. The current study tested a smaller dose (2.5 mg) of terbutaline and seems to have nailed the matter squarely. It seems, therefore, that terbutaline can be added to other existing strategies for reduction of nocturnal hypoglycemia. These other strategies include bedtime caloric supply, recalibration of antidiabetic medications, limitation of alcohol intake, exercise counseling, self-blood glucose monitoring (especially in the ‘wee' hours), prompt recognition and intervention for hypoglycemia unawareness, among others. The fact that the study included just 15 patients with type 1 diabetes is an obvious limitation. Therefore, a larger study expanded to even patients with type 2 diabetes (many of whom are also at risk for hypoglycemia) would be most welcome.

The FDA is notifying health care professionals -- specifically, family physicians and OB-Gyns -- that it is requiring the addition of a new boxed warning and contraindication to terbutaline's drug labeling to warn health care professionals about the severe cardiovascular and other risks these products pose for pregnant women. FDA officials also have agreed to reclassify terbutaline from a pregnancy category B drug to a pregnancy category C drug in response to a 2008 citizen petition.wisepoqder β-agonist Powder

Terbutaline is approved to prevent and treat bronchospasm associated with asthma, bronchitis and emphysema, but the drug also has been used off-label for obstetric purposes, including treating preterm labor and uterine hyperstimulation. In addition, terbutaline has been used for longer periods of time to prevent recurrent preterm labor.

However, new safety information reviewed by the FDA indicates that death and serious adverse reactions, including increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia, have been reported after prolonged administration of oral and injectable terbutaline to pregnant women.

In a Feb. 17 safety alert(www.fda.gov), the FDA acknowledged that administering terbutaline by injection to a pregnant women in urgent obstetrical situations within a hospital setting may be appropriate based on a physician's clinical judgment. However, the agency said terbutaline administered by injection or by continuous infusion pump should not be used beyond 48-72 hours. The agency also emphasized that injectable terbutaline should not be used in the outpatient or home setting.

Furthermore, the FDA said oral terbutaline is contraindicated for the treatment or prevention of preterm labor because it has not been shown to be effective and has safety concerns similar to those associated with the injectable form of the drug.

The agency advised that women who are taking terbutaline for asthma or other medical conditions should talk with their physician if they are pregnant or become pregnant to determine whether use of the drug should be discontinued.

A VERY LOW DOSE of tamoxifen—5 mg/d, given for 3 years rather than 5 years—halved the risk of breast cancer recurrence or new lesions over placebo in women with breast intraepithelial neoplasia, without producing the usual toxicities seen with the standard dose, Italian researchers reported at the 2018 San Antonio Breast Cancer Symposium.1wisepoqder Tamoxifen

“We believe our results have external validity and—given their pragmatic nature and the easy accessibility of tamoxifen—are generalizable,” said Andrea De Censi, MD, of the National Hospital E.O. Ospedali Galliera–Division of Medical Oncology in Genoa, Italy. “Tamoxifen, 5 mg a day (splitting the tablet) or 10 mg every other day, is applicable in clinical practice tomorrow.”

Breast cancer experts at the meeting said this is news they can use. “Looking at these data, I would definitely give lower doses of tamoxifen, especially in patients with atypical ductal hyperplasia and lobular carcinoma in situ,” said Virginia G. Kaklamani, MD, Professor of Medicine at The University of Texas at San Antonio and leader of the Breast Cancer Program at The University of Texas MD Anderson Cancer Center, Houston.

“This information tells me I can perhaps cut back on the dose for patients who are not tolerating tamoxifen. This would help me keep them on the dose, rather than have them abandon therapy,” said John Cole, MD, of the Ochsner Health System in New Orleans.

ALTHOUGH TAMOXIFEN is effective in preventing breast cancer recurrence, its side effects—menopausal symptoms, endometrial cancer, deep-vein thrombosis, and pulmonary embolism— are barriers for its use as a preventive measure. The aim of this de-escalation study was to determine whether a lower dose and shorter duration of tamoxifen therapy would be as efficacious as and better tolerated than the standard dose.

Dr. De Censi and colleagues had previously shown that a dose as low as 1 mg/d is noninferior to 20 mg in decreasing Ki67 (a marker of proliferation), though less effective in modulating serum biomarkers.2 For the current study, the investigators decided 5 mg/d would be a reasonable compromise between activity and safety. He explained that the government- and charity-funded study could not afford to financially support the use of a very large noninferiority trial of tamoxifen at 20 mg/d for 5 years as the control arm.